Arcutis: Arcutis Biotherapeutics, Inc. Launches Zoryve (Roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 Years

Arcutis Biotherapeutics, Inc. announced the commercial launch of ZORYVE®? (roflumilast) cream 0.05% for the treatment of mild to moderate atopic dermatitis in children ages 2 to 5 years in the United States. ZORYVE cream 0.05% is a once-daily, steroid-free topical treatment that provides long-term disease control with no limitation on duration of use. In clinical trials, ZORYVE cream0.05% had positive results across all efficacy endpoints, including significant clearance of atopic dermatitis signs and symptoms and meaningful improvement in itch. This launch expands the ZORYVE portfolio to a younger pediatric population, making ZORYVE cream available for children with mild to moderate atopic dermat inflammation as young as 2 years old. ZORYVE cream 0.,05% will be available in pharmacies this week. The product is being reviewed by commercial pharmacy benefit managers and other plans to enable similar coverage as the entire ZORYVE portfolio. The ZORYVE®? Direct Program helps patients access their prescribed Arcutis medication. Specifically, this patient support program helps those who have been prescribed ZORYVE to navigate the payer process, assists patients with adherence, and includes the ZORYVE Direct Savings Card Program, which can help reduce out-of-pocket costs for eligible commercially insured patients.+ Arcutis will also continue to offer the Arcutis Cares?? patient assistance program (PAP) that provides ZORYVE at no cost for financially eligible patients who are uninsured or underinsured.